New obesity drug REGN20934 enters first human safety trial

NCT ID NCT07594093

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This Phase 1 study tests a new drug called REGN20934 in 90 adults who are overweight or obese. The main goal is to check the drug's safety, side effects, and how the body processes it. Participants receive a single dose of either the drug or a placebo, and researchers monitor them closely. This is an early step to see if the drug is safe enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN20934
What this could lead to: If successful, this early study could pave the way for a new weight management drug.
What could go wrong: This is a very early Phase 1 trial focused on safety, not weight loss. It involves only 90 people and may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Locations

California Clinical Trials Medical Group
RECRUITING

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.